Reproductive Medicine Associates of New Jersey
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, Reproductive Medicine Associates of New Jersey sits in the top decile of US sponsors by registered trial count (#372 of 15,742 sponsors by registered trial count).
Reproductive Medicine Associates of New Jersey: 51 sponsored US clinical trials, 7 recruiting.
Reproductive Medicine Associates of New Jersey sponsors 51 registered US clinical trials on ClinicalTrials.gov, 7 of them currently recruiting, and 38 completed. 1 of these trials are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Infertility, with 6 trials.
Top-decile sponsor footprint
Reproductive Medicine Associates of New Jersey ranks in the top decile of sponsors by registered trial count (#372 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
38 of 44 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (86.4%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 4 | 1 |
Where Reproductive Medicine Associates of New Jersey enrollment is open (later-stage tilt)
7 recruiting of 51 indexed (14% open); 38 completed (75%).
Phase mix: 1 late (III/IV) vs 0 early (I/II) (later-stage heavy).
Top condition: Infertility (6 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Reproductive Medicine Associates of New Jersey: open-pipeline peers nationwide
Peers matched on 51 registered trials and 14% open enrollment, not the therapeutic-area sidebar.
Reproductive Medicine Associates of New Jersey sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 51 trials (± recruiting share)
- Colgate Palmolive · 51 trials · 6% recruiting
- MedtronicNeuro · 51 trials · 4% recruiting
- Ohio University · 51 trials · 10% recruiting
- Texas Woman's University · 51 trials · 6% recruiting
Sponsors near 14% open enrollment (± trial volume)
- Lindenwood University · 14% recruiting · 29 trials
- Virginia Commonwealth University · 14% recruiting · 558 trials
- Fate Therapeutics · 14% recruiting · 22 trials
- InMode MD · 14% recruiting · 22 trials
Related
What to do with this Reproductive Medicine Associates of New Jersey page
51 registered trials is a research-attention snapshot, not an endorsement of Reproductive Medicine Associates of New Jersey or any single study.
- 7 of Reproductive Medicine Associates of New Jersey's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Infertility is the condition Reproductive Medicine Associates of New Jersey studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Infertility trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Reproductive Medicine Associates of New Jersey pipeline card: 51 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.